Ali Stunt, founder and chief executive of Pancreatic Cancer Action - TopicsExpress



          

Ali Stunt, founder and chief executive of Pancreatic Cancer Action said: “This recommendation is bad news for pancreatic cancer patients, their families and loved ones, who will rightly be angered by NICE’s position. Pancreatic cancer has the worst survival outcomes of any of the most common cancers and we badly need new treatments like Abraxane to be approved. telegraph.co.uk/health/healthnews/11081589/New-drug-for-pancreatic-cancer-turned-down.html
Posted on: Tue, 09 Sep 2014 08:12:21 +0000

Trending Topics



Recently Viewed Topics




© 2015